目的  为抗体偶联药物(antibody-drug conjugate, ADC)研发提供参考。方法   依托科睿唯安Cortellis数据库，通过检索全球ADC的上市情况、研发地域分布、药物适应症分布及临床试验部分管线等数据，分析目前ADC的整体研发态势和全球布局。结果   截至2020年11月20日，全球处于活跃状态的ADC共414个，其中已上市10个；美国ADC研发数量居全球首位，中国位居第二；ADC主要用于乳腺癌、卵巢癌、淋巴瘤、肺癌、胃癌等癌症治疗；国际在研管线中，靶点分布较为多样化，国内在研管线则相对集中，主要聚焦于人类表皮生长因子2。结论   对ADC的研发态势和全球布局进行了全面分析，为我国ADC的研发提供了参考。

Objective  To provide references for the development of antibody-drug conjugate(ADC). Method   Based on Cortellis database, overall development situation and global layout of ADCs were analyzed by searching the global marketing status, research and development region distribution, drug indications and pipelines of ADC clinical trials. Results  Until November 20,2020, there were 414 active ADC worldwide, 10 of which were launched. United States ranked first in the number of ADCs in development, while China ranked second. ADCs were mainly used in treatment of breast cancer, ovarian cancer, lymphoma, lung cancer, gastric cancer,etc. Target distribution in worldwide development pipeline was relatively diversified, while relatively concentrated in China, mainly focusing on human epidermal growth factor receptor 2. Conclusion  The comprehensive analysis of development situation and global layout of ADCs serves  provide reference for China ADC research and development.